Locally Advanced Urothelial Cancer
Drug | Drug Name | Drug Description |
---|---|---|
DB13007 | Enfortumab vedotin | An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB13007 | Enfortumab vedotin | Cytochrome P450 3A4 | enzyme |
DB13007 | Enfortumab vedotin | Nectin-4 | target |
DB13007 | Enfortumab vedotin | P-glycoprotein 1 | transporter |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB15766 | Retifanlimab | 2 | Completed | 1 |
DB17391 | Trastuzumab vedotin | 2 | Recruiting | 1 |